Seeing "Made in China" from a single drug-a leap from generic drugs to independent innovation

The speed and quantity of new crown vaccine research and development have always been in the world's first square.

As the "national team" for drug research and development, the new crown vaccine developed by Sinopharm was included in the WHO emergency use list on May 7.

Independence and self-reliance

A hundred years after the founding of the party, a "coating machine" in the shape of a roller was exhibited at Sinopharm Group, quietly telling the history of the Chinese people's fight against infectious diseases

This machine is used to produce "sugar pills" for polio vaccine

At that time, Gu Fangzhou, who was in his 30s, was in danger and was ordered to start research on polio

"Science and technology in the world, in the final analysis, must be self-reliant

Since 1994, there have been no cases of polio caused by a native wild virus in our country, and the "sugar pill" has become a "sweet" memory of the childhood of generations of Chinese people

Maintaining the health of the people has been the constant pursuit of the Chinese Communist Party for a century

The time comes to the beginning of 2020.

From the start of the new crown vaccine project to the world’s first clinical research, it only took 2 months; to the first emergency use of vaccines in China’s history, it only took 4 months; to the first overseas phase III clinical trials of vaccines in China’s history, only It took 5 months; it only took 11 months to get the conditional listing approval

At present, while continuously building the domestic immune barrier, China has already included 2 vaccines of Sinopharm and Kexing on the WHO emergency use list, and 4 vaccines on the list of new crown vaccine products available for export, in order to build human health and health.

The original innovative drugs are entering the harvest period

Not only are there "national teams", more and more pharmaceutical companies are also achieving results at the forefront of innovation

In late June, the combined use of Daboshu and Dayoutong was approved for marketing, becoming the world's first PD-1 immune combination therapy approved for liver cancer patients

After the founding of New China, China gradually had an independent industrial system, and the shortage of medicines and medicines was alleviated

In 2008, as a component of China's mid- and long-term scientific and technological development plan, multiple departments implemented the "Major New Drug Creation and Manufacturing" major scientific and technological project, which promoted the gradual transformation of China's new drug development from imitation-based to creation-based

In 2011, China's first small-molecule targeted anti-cancer drug icotinib hydrochloride with completely independent intellectual property rights was born in Zhejiang.

During the "13th Five-Year Plan" period, more than one-fifth of the country's first-class innovative drugs were cultivated in Shanghai alone
.
In 2020, the scale of Shanghai Pudong's biopharmaceutical industry will exceed 80 billion yuan, and a total of 11 Class I new drugs will be listed
.

"In order to allow the majority of patients to use Chinese good medicines as soon as possible, the scientific research team has been continuously researching drug innovation for more than ten years or even decades, and has achieved breakthrough results by putting the'cold bench on the hot bench'
.
" Grinding a sword, with the initial establishment of the national drug innovation technology system, the reform of the drug review and approval system continues to deepen, and the original innovative drugs are entering the harvest period
.

Good medicine is more affordable

With good medicine, the key is to make it accessible and affordable to the people
.
Focusing on the people and seeking happiness for the Chinese people, the original intention of the Communist Party of China has not changed
.

On June 23, the fifth batch of national-organized centralized drug procurement was opened in Shanghai.
The 251 products to be selected were reduced by an average of 56%, which was the largest national-organized centralized drug procurement
.

The normalized and institutionalized implementation of centralized national drug procurement has transformed institutional advantages into governance efficiency, and effectively reduced the burden on patients
.
Hu Yinglian, a professor at the Central Party School (National School of Administration), believes that drug governance has changed from focusing on treating diseases to focusing on people's health, paying more attention to drug quality and safety and promoting innovation
.

Adhere to the "four aspects" of scientific and technological innovation, including "facing the people's life and health"
.
Starting from the urgent and long-term needs of the country, a number of key core technologies in the fields of medicines, medical devices, medical equipment, vaccines, etc.
are accelerating breakthroughs
.

Looking forward to the "14th Five-Year Plan", it has become a consensus to build a healthy China, deepen the reform of the medical and health system, and lead the high-quality development of the medical field with innovation
.
The state will also build a support platform for Chinese medicine science and technology, reform and improve the Chinese medicine review and approval mechanism, and promote the research, development, protection and industrial development of new Chinese medicines
.